Key result
A patient with suspected atypical neuroleptic malignant syndrome following rapid conversion of ziprasidone to risperidone successfully responded to antipsychotic cessation, dantrolene, and bromocriptine.
Case Report (n=1)
Early detection and sequential treatment with antipsychotic cessation, dantrolene, and bromocriptine can be effective for atypical neuroleptic malignant syndrome.
Answers are grounded in this paper and cite their sources.
Rapid antipsychotic conversion without titration may trigger atypical NMS; leaves open whether gradual switches reduce risk in psychiatric patients.
Neuroleptic malignant syndrome (NMS), which is considered a neurologic emergency, is believed to be caused by exposure to dopamine antagonist or withdrawal from a dopamine agonist. This article reports a case of suspected atypical NMS in a patient following rapid conversion of ziprasidone to risperidone without titration. While the initial presentation did not fully meet the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, diagnostic features, a sequential treatment strategy was initiated and the patient appropriately responded to antipsychotic cessation in addition to combination therapy with dantrolene and bromocriptine. Neuroleptic malignant syndrome diagnostic criteria, treatment, and prognosis are discussed.
No takes yet. Share an insight, caveat, or question.
Vickery et al. (2017) conducted a case report in Atypical neuroleptic malignant syndrome (n=1). Antipsychotic cessation and combination therapy with dantrolene and bromocriptine was evaluated on Clinical response. A patient with suspected atypical neuroleptic malignant syndrome following rapid conversion of ziprasidone to risperidone successfully responded to antipsychotic cessation, dantrolene, and bromocriptine.
Synapse has enriched 10 related papers. Consider them for comparative context: